Transfusion and Apheresis Science
Volume 28, Issue 1 , Pages 93-100 , February 2003

The Norwegian plasma fractionation project––a 12 year clinical and economic success story

  • O. Flesland

      Affiliations

    • Blood Bank, Baerum Hospital, N-1306 Barum, Norway
    • Institute of Immunology, Rikshospitalet University Hospital, N-0027 Oslo, Norway
    • Corresponding Author InformationCorresponding author. Address: Blood Bank, Baerum Hospital, N-1306 Barum, Norway. Tel.: +47-6780-9703; fax: +47-6780-9705
    • ,
  • J. Seghatchian

      Affiliations

    • Blood Component Technology and Thrombosis/Haemostasis Consultancy, 50 Primeroe Hill Road, London NW3 3AA, UK
    • ,
  • B.G. Solheim

      Affiliations

    • Institute of Immunology, Rikshospitalet University Hospital, N-0027 Oslo, Norway

References 

  1. Evensen SA, Ulstrup J, Skaug K, Fröland SS, Glomstein A, Rollag H. HIV infection in Norwegian haemophiliacs: the prevalence of antibodies against HIV in heamophiliacs treated with lyophilized cryoprecipitate from volunteer donors. Eur. J. Haematol. 1887;39:44–48
  2. Solheim BG, Heier HE, Evensen SA. Self-sufficiency for blood and plasma products in Norway. Biol. Clin. Heamtol. 1992;14:103–105
  3. Retningslinjer for GMP i blodbanker. Statens helsetilsyns veiledningsserie 1-1996. Oslo: Statens helsetilsyn; 1996
  4. Nordoy I, Schrumpf E, Elgjo K, Flesland O, Andersen Glende J, Orjasaeter H, et al.  Liver disease in anti-hepatitis C virus-positive Norwegian blood donors. Scand. J. Gastroenterol. 1994;29:77–81
  5. Aukrust P, Muller F, Svenson M, Nordoy I, Bendtzen K, Fronland SS. Administration of intravenous immonolobulin (IVIG) in vivo––down-reguolatory effects on the IL-1 system. Clin. Exp. Immunol. 1999;115:136–143
  6. Gullestad L, Aass H, Fjeld JG, Wikeby L, Andreassen AK, Ihlen H, et al.  Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure. Circulation. 2001;103:220–225
  7. Aukrust P, Gullestad L, Lappegard KT, Ueland T, Aass H, Wikeby L, et al.  Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunolglobulin treatment. Circulation. 2001;104:1494–1500
  8. Solheim BG, Svennevig JL, Mohr B, Dragsund M, Noddeland H, Töllöfsrud S, et al.  The use of Octaplas in patients undergoing open heart surgery. In:  Müller-Berghaus G,  Madlener K,  Blombäck M,  Ten Cate JW editor. DIC Pathogenesis and Disseminated Intravascular Fibrin Formation. Amsterdam: Excerpta Medica, Elsevier Science Publishers; 1993;p. 253–262
  9. Solheim BG, Eggen BM, Heier HE. Self-sufficiency for plasma and plasma proteins in Norway. In:  Sibrowski W,  Stangel W,  Blauhut B editor. Transfusionsmedizin 1995/96. vol. 33:Beitr Infusionsther Transfusionsmed; 1966;p. 98–102
  10. Solheim BG, Rollag H, Svennevig JL, Arafa O, Fosse E, Bergerud U. Viral safety of solvent/detergent treated plasma. Transfusion. 2000;40:84–90
  11. Noddeland H, Tølløfsrud S, Svennevig JL, Bentsen G, Brosstad F, Solheim BG. Universal solvent/detergent(SD)-treated plasma (Uniplas®) rationale and clinical properties. Thromb Res. 2002;107:533–537
  12. Tollefsrud S, Noddeland H, Svennevig JL, Berntsen G, Mollens TE, Solheim BG. Universal fresh frozen plasma (Uniplas®)––a safe product in open heart surgery, submitted for publication
  13. Rollag H, Solheim BG, Svennevig JL. Viral safety of blood derivatives by immune neutralization. Vox Sang. 1998;74(Suppl 1):213–221
  14. Nordbo A, Andersen A, Kongsgaard UE, Bormer OP, Olsen H. Pharmaceutical-grade albumin: impared drug-binding capacity in vitro, in preparation
  15. Haubelt H, Blome M, Kiessling AH, et al.  Effects of solvent/detergent-treated plasma and fresh-forzen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang. 2002;82:9–14
  16. Mast AE, Stadanlick JE, Lockett JM, Dietzen DJ. Solvent/detergent-treated plasma has decreased antitrypsin activity and absent antiplasmin activity. Blood. 1999;94:3922–3927
  17. Hellstern P, Sachse H, Schwinn H, Oberfrank K. Manufacture and in vitro characterization of solvent/detergent-treated human plasma. Vox Sang. 1992;63:178–185
  18. Beeck H, Hellstern P. In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma. Vox Sang. 1998;74(Suppl 1):219–223
  19. Leebeek FWG, Schipperus MR, van Vliet HHDM. Coagulation factors in solvent/dergent treated plasma. Transfusion. 1999;39:1150–1151
  20. Zeiler T, Wittmann G, Zimmermann R, et al.  The effect of virus inactivation on coagulation factors in therapeutic plasma. Br. J. Haematol. 2000;111:986–987
  21. Matsuda M, Wakabayashi K, Aoki N, Morioka Y. Alpha 2-plasmin inhibitor is among acute phase reactants. Thromb. Res. 1980;17(Suppl):527–532
  22. Hart H, Jones A, Cubie H, McIntosh RV, Cuthbertson B. Distrubution of hepatitis A antibody over a process for the preparation of a high-purity factor VIII concentrate. Vox Sang. 1994;67(Suppl 1):51–55
  23. Wood DJ, Bird CR, Thorpe R, Barrowcliffe TW. Hepatitis A virus antibody levels in factor VIII concentrates. Lancet. 1994;344:202–203
  24. Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. BMJ 1998;317:235–40

PII: S1473-0502(02)00104-0

doi: 10.1016/S1473-0502(02)00104-0

Transfusion and Apheresis Science
Volume 28, Issue 1 , Pages 93-100 , February 2003

Article Tools

* Image Usage & Resolution